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Candidemia has become an important bloodstream infection that is frequently associated with high rates of mortality andmor-
bidity, and its growing incidence is related to complex medical and surgical procedures. We conducted a multicenter study in
five tertiary care teaching hospitals in Italy and Spain and evaluated the epidemiology, species distribution, antifungal suscepti-
bilities, and outcomes of candidemia episodes. In the period of 2008 to 2010, 995 episodes of candidemia were identified in these
hospitals. The overall incidence of candidemia was 1.55 cases per 1,000 admissions and remained stable during the 3-year analy-
sis. Candida albicans was the leading agent of infection (58.4%), followed by Candida parapsilosis complex (19.5%), Candida
tropicalis (9.3%), and Candida glabrata (8.3%). The majority of the candidemia episodes were found in the internal medicine
department (49.6%), followed by the surgical ward, the intensive care unit (ICU), and the hemato-oncology ward. Out of 955
patients who were eligible for evaluation, 381 (39.9%) died within 30 days from the onset of candidemia. Important differences
in the 30-day mortality rates were noted between institutions: the lowest mortality rate was in the Barcelona hospital, and the
highest rate was in the Udine hospital (33.6% versus 51%, respectively; P 0.0005). Overall, 5.1% of the 955 isolates tested were
resistant or susceptible dose dependent (SDD) to fluconazole, with minor differences between the hospitals in Italy and Spain
(5.7% versus 3.5%, respectively; P 0.2). Higher MICs for caspofungin were found, especially with C. parapsilosis complex
(MIC90, 1g/ml). Amphotericin B had the lowest MICs. This report shows that candidemia is a significant source of morbidity
in Europe, causing a substantial burden of disease andmortality.
Candida is an important cause of bloodstream infections(BSIs), leading to significant mortality and morbidity in
health care settings. The incidence of candidemia is growing with
the increasing complexity of surgical procedures, the existence of
patient populations who are at higher risk of infection, and
changes in patient demographics. The global incidence of candi-
demia increased 5-fold in the past 10 years, and Candida spp. are
currently between the fourth and the sixth most common noso-
comial bloodstream isolates found in studies done in the United
States and Europe (1, 2). However, candidemia rates vary geo-
graphically. For example, an increasing incidence of candidemia
in Iceland was reported for the period between 1980 and 1999 (3)
but the same was not observed in Switzerland, where a national
surveillance study showed that the incidence of candidemia had
remained unchanged between 1991 and 2000 (2). Therefore, it
seems that differences do exist in the epidemiology of candidemia
between different countries, underscoring the need for continu-
ous surveillance tomonitor trends in the incidence, species distri-
bution, and antifungal drug susceptibility profiles. The epidemi-
ology of candidemia has been studied extensively in the United
States, Europe, and some countries in South America (4–16).
Candidemia remains associated with high crude and attribut-
able mortality rates and with increased costs of patient care and
duration of hospitalization. The attributable mortality rates have
been reported to range from 5% to 71%, and crudemortality rates
have been reported to be as high as 81% (4–6, 14, 17–19). In terms
of species ofCandida, recently, a shift toward non-albicans species
was reported by some authors, especially in hematological, trans-
planted, and intensive care unit (ICU) patients (12, 20, 21).
A reduced antifungal susceptibility in non-albicans Candida
species and a correlation with routine fluconazole prophylactic
use has been suggested (15). Intrinsic and emerging resistance to
azoles represents a major challenge for empirical therapeutic and
prophylactic strategies (5).
This study was performed to evaluate the contemporary epide-
miology, species distribution, antifungal susceptibilities, and out-
comes of candidemia episodes in five big teaching hospitals in
Italy and Spain.
MATERIALS AND METHODS
The study was conducted in five tertiary care teaching hospitals in Italy
and Spain: (i) Trieste University Hospital (700 beds) in Trieste, Italy, (ii)
SantaMariaMisericordiaUniversityHospital (1,200 beds) inUdine, Italy,
(iii) Policlinico Gemelli (1,500 beds) in Rome, Italy, (iv) Val d’Hebron
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Hospital (1,150 beds) in Barcelona, Spain, and (v) Virgen Del Rocio Uni-
versity Hospital (851 beds) in Seville, Spain. All patients admitted to these
five hospitals who developed candidemia in the period of January 2008 to
December 2010 were included in the study and prospectively followed.
Patients with at least one positive blood culture for Candida spp. and a
compatible clinical illness were identified through the microbiological
laboratory database, and all information was recorded in an electronic
database. For each patient, only the first episode of candidemia was re-
corded. Patients whose cultures grew 1 species of Candida were ex-
cluded from the analysis. Patients with candidemia were followed pro-
spectively for 30 days or until their discharge from the hospital. Outcomes
were recorded only for patientswith30 days of follow-up after the initial
episode of candidemia.
During the study period, there were no changes in microbiological
laboratory techniques in the five hospitals. Candida species were isolated
from blood samples using the Bactec 860 system (Becton, Dickinson, Inc.,
Sparks, MD). The species were identified using the API ID 32C system
(bioMérieux, Marcy l’Etoile, France) or the Vitek 2 system (bioMérieux).
In the cases of inconclusive results obtained by both systems, isolates were
definitively identified using supplemental tests, e.g., by the presence or
absence of well-formed pseudohyphae on cornmeal-Tween 80 agar and
growth at 42 to 45°C. The last test was also required to differentiate isolates
ofC. albicans from those ofCandida dubliniensis. Antifungal susceptibility
testing to amphotericin B, caspofungin, fluconazole, itraconazole, and
voriconazole was performed using the Sensititre YeastOne colorimetric
plate (Trek Diagnostic Systems, Cleveland, OH). MIC results were inter-
preted according to species-specific clinical breakpoints as established by
the Clinical and Laboratory Standards Institute (CLSI) for amphotericin
B, caspofungin, fluconazole, itraconazole (only with C. albicans), and
voriconazole (22, 23).
The chi-square test or Fisher’s exact test was used to compare categor-
ical variables. Differences between the groups were considered to be sig-
nificant for variables yielding a P value of0.05.
This study was approved by the local institutional review boards, and
written patient consent was not required because of the observational
nature of this study.
RESULTS
A total of 995 episodes of candidemia were identified during the
study period (January 2008 to December 2010). The median pa-
tient agewas 66.2 years old and 57%weremales. The demographic
and clinical characteristics of the patients are summarized inTable
1. The majority of patients (93.1%) had one or more comorbidi-
ties at the time of candidemia diagnosis. Four hundred forty-one
patients (46%) had undergone a surgical intervention, 285 (30%)
had a solid tumor, 275 (28.8%) had cardiovascular diseases, 242
(25.3%) were diabetic, 60 (6.3%) had hematological malignan-
cies, 33 (3.4%) received a solid organ transplantation, and 19 (2%)
had human immunodeficiency virus (HIV) infection. The overall
incidence of candidemia was 1.55 cases per 1,000 admissions and
remained stable during the 3-year analysis. As shown in Table 2,
the incidences differed across hospitals, with the highest incidence
in Rome (2.53 cases per 1,000 admissions), and the lowest in
Udine (0.8 per 1,000 admissions).
C. albicanswas the leading cause of infection (58.4%), followed
by C. parapsilosis complex (19.5%), C. tropicalis (9.3%), and C.
glabrata (8.3%). C. albicans accounted for50% of infections in
all 3 Italian hospitals and in the hospital in Barcelona, Spain; only
in Seville did non-albicans Candida species represent50%of the
isolates. The distribution of C. albicans and non-albicans Candida
strains differed according to the patient population and risk fac-
tors, as shown in Fig. 1. In hemato-oncology patients, C. albicans
was isolated in 41.8% of the cases, C. tropicalis in 20%, and C.
TABLE 1 Characteristics of 955 episodes of candidemia stratified by hospital
Patient characteristic
Data by hospital (n)a
Total (955)U (126) T (140) R (456) B (131) S (102)
Age (mean [SD]) (yr) 64.4 (21.4) 75.9 (16.1) 65 (15) 61 (19) 59.1 (14) 66.2 (13)
Male sex (n [%]) 79 (63) 73 (52) 252 (55.2) 82 (62.6) 54 (52.9) 486 (57)
Underlying disease/history (n [%])
Surgery 54 (43) 27 (38) 242 (53.2) 68 (52) 50 (49) 441 (46)
Solid organ transplantation 4 (3.2) 0 19 (4.2) 6 (4.5) 4 (3.9) 33 (3.4)
Hematologic malignancy 12 (10) 3 (4) 24 (5.2) 9 (6.9) 12 (11.8) 60 (6.3)
HIV 3 (2.49) 1 (1) 1 (1.1) 8 (6.1) 6 (5.9) 19 (2)
Solid tumor 47 (37.3) 39 (55) 153 (33.5) 11 (11.5) 35 (34.3) 285 (30)
Cardiovascular disease 72 (57) 12 (17) 143 (31.3) 30 (31) 18 (17.6) 275 (28.8)
Diabetes mellitus 27 (21.5) 26 (36) 100 (21.9) 68 (71.2) 21 (20.6) 242 (25.3)
Distribution of different Candida species
(n [%/rank])
C. albicans 79 (63/1) 77 (55/1) 274 (60.1/1) 78 (59.5/1) 50 (48.1/1) 558 (58.4/1)
C. parapsilosis complex 22 (17.4/2) 34 (24/2) 87 (19.1/2) 20 (15.3/2) 23 (22.1/2) 186 (19.5/2)
C. glabrata 11 (8.7/3) 14 (10/3) 33 (7.2/4) 14 (10.7/4) 7 (6.7/4) 79 (8.3/4)
C. tropicalis 9 (7.1/4) 6 (4/4) 38 (8.3/3) 15 (11.4/3) 21 (20.2/3) 89 (9.3/3)
Non-albicans Candida spp. 5 (2.4/5) 9 (7/5) 24 (5.2/5) 4 (3.11/5) 3 (2.9/5) 45 (4.7/5)
a U, Udine; T, Trieste; R, Rome; S, Seville; B, Barcelona.
TABLE 2 Incidence of candidemia in the study period
Hospital
Mean incidence (no. of episodes/1,000 admissions)
by period:
2008 2009 2010 2008–2010
Udine, Italy 0.73 0.79 0.84 0.8
Trieste, Italy 2.11 1.73 1.4 1.74
Rome, Italy 2.35 2.53 2.71 2.53
Barcelona, Spain 1.6 1.57 1.54 1.55
Seville, Spain 0.98 1.08 1.25 1.12
Overall 1.55 1.54 1.71 1.55
Bassetti et al.
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glabrata in 16.4%; in the internal medicine ward, the ICU, and the
surgery ward, C. albicans accounted for around 60% of the cases.
The majority of the candidemia episodes were found in the
internal medicine department (49.6%), followed by the surgery,
ICU, and hemato-oncology wards (Table 3).
Crude mortality rates stratified by hospital and ward are re-
ported in Table 3. Out of 955 evaluable patients, 381 (39.9%) died
within 30 days from the onset of candidemia. Important differ-
ences in the 30-day mortality rates were noted between institu-
tions: the lowest mortality rate was in the hospital in Barcelona,
and the highest rate was in the hospital in Udine (33.6% and 51%,
respectively; P 0.0005).
Regarding the crude mortality rates in the different units, pa-
tients in hemato-oncology wards had the highest mortality rate
(56.9%), followed by patients in the ICU (46%) and in the internal
medicine wards (45.9%). Patients in general surgery showed the
lowest mortality rate of all the centers, with a mean rate of 18.7%.
Table 4 shows the in vitro activities of 5 systemically active
antifungal agents tested against 955 BSI isolates of Candida spp.
based on CLSI breakpoints (23). The rates of susceptibility to flu-
conazole were 98.6% for C. albicans and 97.3% for C. parapsilosis
complex. Decreased susceptibility to fluconazole was mostly seen
with C. glabrata (54.4%) and C. tropicalis (94.9%). Overall, 5.1%
of the 955 isolates tested were resistant, intermediate, or suscepti-
ble dose dependent (SDD) to fluconazole.HigherMICs for caspo-
fungin were found in C. albicans, C. glabrata, and especially in C.
parapsilosis complex (MIC90, 1 g/ml), which had 5 resistant
strains (2.7%). Amphotericin B had the lowest MIC values. Some
0,00%
10,00%
20,00%
30,00%
40,00%
50,00%
60,00%
70,00%
80,00%
90,00%
100,00%
C. krusei
C. tropicalis
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C. parapsilosis
C. albicans
FIG 1 Distribution (%) of Candida species according to underlying pathology or medical care.
TABLE 3 Thirty-day crude mortality rates and distributions of candidemia in hospital wards
Distribution of candidemia episodes/
mortality rate by hospital ward
Data by hospital (n)a
Total (955)U (126) T (140) R (456) B (131) S (102)
Overall 30-day mortality rate (n [%]) 64 (51)b,c 63 (45) 178 (39.9)c 44 (33.6)b 32 (31.4)b 381 (39.9)
Internal medicine
n (%) 72 (57) 95 (67.8) 237 (56.9) 42 (32) 29 (28.4) 475 (49.7)
30-day mortality rate (n [%]) 42 (52.3)b,c 48 (51.5) 108 (45.6) 13 (33.3)b 7 (24)b 218 (46)
Hemato-oncology
n (%) 12 (10) 0 (0) 24 (5.3) 11 (8.4) 11 (10.8) 58 (6.1)
30-day mortality rate (n [%]) 8 (67)b 0 (0) 16 (66.6) 4 (36.4)b 5 (45.5) 33 (56.9)
Intensive care
n (%) 20 (16) 22 (15.7) 59 (12.9) 42 (32) 44 (43.1) 187 (19.6)
30-day mortality rate (n [%]) 10 (50) 9 (41) 29 (49.1) 20 (47.6) 18 (41) 86 (46)
General surgery
n (%) 22 (17) 23 (16.4) 136 (29.8) 36 (27.5) 18 (17.6) 235 (24.6)
30-day mortality rate (n [%]) 4 (18) 6 (26) 25 (18.4) 7 (19.4) 2 (11.1) 44 (18.7)
a U, Udine; T, Trieste; R, Rome; S, Seville; B, Barcelona.
b U versus B and S, P 0.0005.
c U versus R, P 0.002.
Epidemiology and Susceptibility of Candidemia in Europe
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minor differences were found for fluconazole resistance in all
Candida species between the hospitals in Italy and Spain (5.7%
versus 3.5%; P 0.2).
DISCUSSION
Several studies have shown a substantial increase in the incidence
of candidemia in the past 2 decades. Our data show that in the 5
hospitals we analyzed, the incidence of candidemia has increased
steadily in two of the institutions (Rome Catholic Hospital and
Seville Hospital) and has remained stable in the other three. The
mean rates are higher than those reported for centers in the
NorthernHemisphere, including the United States (0.42 cases per
1,000 admissions) (24), Canada (0.45 per 1,000 admissions) (25),
and some European countries (0.20 to 1.09 cases per 1,000 admis-
sions) (26), but they are much higher than those reported in Fin-
land (0.026 to 0.03 cases per 1,000 admissions [27]). The differ-
ences in candidemia rates between these countries may reflect
differences in the representativeness and age distributions of the
study populations, variations in health care practices, blood cul-
ture patterns, and antibiotic usage and resistance patterns.
Over the past 10 years, some studies have reported a shift in the
etiology of candidemia. While C. albicans is still considered to be
themost common species that causes candidemia, increasing rates
of candidemia caused by C. tropicalis, C. parapsilosis species com-
plex, C. glabrata, and Candida krusei have been reported world-
wide (28–31). The reasons for the emergence of non-albicansCan-
dida species are not completely understood, but some medical
conditions may consistently impact the risk of developing candi-
demia due to non-albicans Candida species: C. parapsilosis com-
plex fungemia has been associated with vascular catheters and
parenteral nutrition (28), C. tropicalis candidemia is associated
with cancer and neutropenia (32), and C. krusei and C. glabrata
fungemias are associated with previous exposure to azoles (15).
The findings from our surveillance do not support these reports.
We observed a predominance ofC. albicans (around 60%) in can-
didemia infections. In our study, C. parapsilosis complex sur-
passed the other non-albicans Candida spp. to become the most
common species isolated after C. albicans. Our series clearly sup-
ports the concept that C. parapsilosis complex accounts for the
large majority of non-albicans Candida species in southern Eu-
rope. The high incidence of candidemia caused by C. parapsilosis
complex has been previously reported in South American and
Italian hospitals (11, 16). Of note, the frequencies of C. glabrata
candidemia in these regions are lower than those reported in the
Northern Hemisphere (33), and their frequency has been sur-
passed by that caused by C. tropicalis. We did not observe impor-
tant differences across countries regarding the species distribu-
tions in the different departments. C. albicans dominated in our
study in internal medicine, surgery, and ICU departments, while
non-albicans Candida spp. occurred frequently among hemato-
oncology patients, confirming previous observations (28). On the
other hand,C. tropicalis candidemiawas foundmore frequently in
elderly patients, as reported elsewhere (34).
Interesting differences emerged in the profiles of patients with
Candida BSIs between our data and those previously described
elsewhere. Latin American and European studies have indicated
that 56.5% and 44.4% of episodes of nosocomial fungemia cases,
respectively, occurred in patients in the ICU(31, 34). In contrast,
only 19.6% of episodes in our study occurred in ICU patients; this
proportion was only a small amount lower than that which oc-
curred in patients in the surgical units (24.6%). In our study, in
contrast with those of other studies, an unusually large proportion
(49.7%) of candidemia infections occurred among patients in a
general internal medicine department, especially in the Italian
TABLE 4 Frequency of antifungal resistance in Candida bloodstream infections according to CLSI breakpoints and MICs
Species (n)
Antifungal
agent
No. (%) of isolates resistant, intermediate, or
SDD to the antifungal agent ina:
Total no. of
nonsusceptible
strains (%
SDD,
intermediate,
or resistant)
MIC50/MIC90 (g/ml) of isolates in:
U T B R S U T B R S
C. albicans
(558)
Amphotericin B NA NA NA NA NA NA 0.06/0.125 0.25/0.5 0.19/0.38 0.06/0.25 0.5/1
Caspofungin 0 0 0 0 0 0 0.06/0.12 0.06/0.12 0.047/0.125 0.03/0.125 0.03/0.06
Fluconazole 2 (3.8) 1 (1) 0 5 (1.8) 0 8 (1.4) 0.25/1 0.12/0.5 0.25/1 0.125/2 0.25/0.5
Itraconazole 2 (6) 1 (1) 18 (23.1) 5 (1.8) 0 26 (4.7) 0.06/0.25 0.06/0.12 0.047/0.5 0.06/0.5 0.03/0.0795
Voriconazole 2 (3.8) 1 (1) 0 4 (1.5) 0 7 (1.2) 0.008/0.06 0.06/0.06 0.016/0.064 0.016/0.125 0.008/0.008
C. parapsilosis
complex
(186)
Amphotericin B NA NA NA NA NA NA 0.06/0.25 0.25/0.5 0.25/0.5 0.03/0.125 0.5/1
Caspofungin 1 (4.5) 0 2 (10) 2 (2.3) 1 (4.3) 5 (2.7) 0.25/1 0.25/0.5 0.125/0.38 0.25/1 0.25/1
Fluconazole 1 (4.5) 1 (3) 0 3 (3.4) 0 5 (2.7) 1/4 0.5/1 0.25/1.5 0.25/1 1/1
Itraconazole NA NA NA NA NA NA 0.06/0.25 0.06/0.25 0.032/0.25 0.06/0.25 0.06/0.125
Voriconazole 2 (9) 0 0 0 0 2 (1) 0.023/0.125 0.06/0.06 0.008/0.047 0.03/0.125 0.008/0.03
C. glabrata
(79)
Amphotericin B NA NA NA NA NA NA 0.125/0.25 0.25/1 0.5/1 0.125/0.25 0.5/1
Caspofungin 0 0 0 0 0 0 0.09/0.125 0.06/0.12 0.064/0.19 0.016/0.06 0.06/0.86
Fluconazole 1 (10) 7 (50) 16 (48.5) 9 (27.3) 3 (42.8) 36 (45.6) 4/8 8/16 3/16 4/128 16/128
Itraconazole NA NA NA NA NA NA 0.25/0.5 0.5/4 1/4 0.06/4 0.5/11.2
Voriconazole NA NA NA NA NA NA 0.045/0.25 0.5/1 0.094/0.19 0.06/8 0.25/2.8
C. tropicalis
(89)
Amphotericin B NA NA NA NA NA NA 0.25/0.5 0.5/1 0.19/0.38 0.125/0.5 1/1
Caspofungin 0 0 0 0 0 0 0.120/0.125 0.06/0.12 0.047/0.125 0.06/0.25 0.06/0.125
Fluconazole 0 0 1 (6.7) 2 (5.3) 1 (4.8) 4 (4.5) 1/2 0.5/4 0.75/2 0.25/2 1/2
Itraconazole NA NA NA NA NA NA 0.25/0.375 0.25/0.5 0.032/1 0.03/0.25 0.25/0.25
Voriconazole 0 0 0 1 (2.6) 2 (9.5) 3 (3.4) 0.015/0.06 0.06/0.5 0.047/0.19 0.03/0.5 0.06/0.125
a SDD, susceptible dose dependent; U, Udine; T, Trieste; R, Rome; S, Seville; B, Barcelona; NA, species-specific clinical breakpoint not available.
Bassetti et al.
4170 jcm.asm.org Journal of Clinical Microbiology
 o
n
 N
ovem
ber 16, 2013 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
hospitals. We hypothesize that this variety of patterns reflects dif-
ferences in the organization and resourcing of health care delivery
practices in various countries rather than significant differences in
the characteristics of the populations studied.
Our proportion of fluconazole-resistant or SDD isolates
(5.1%) was similar to the rates observed for European (6.3%) and
North American (6.6%) hospital isolates (9, 35). Differences in
susceptibilities to fluconazole were observed between Italy and
Spain, with a higher proportion occurring in Italy, but the rates
were lower than those recently reported in a tertiary-care Italian
hospital (12). Voriconazole was the azole that exhibited the best in
vitro antifungal activity. As reported by others (36), caspofungin
demonstrated excellent activity for all the Candida species, except
forC. parapsilosis complex, for which higherMICs were observed.
The clinical relevance of these findings is unknown because the
correlation between MICs and outcomes is still uncertain.
Retrospective cohort studies involving patients with candi-
demia and various underlying diseases have revealed worldwide
crude and attributable mortality rates of 30% to 81% and 5% to
71%, respectively (10). The severity of candidemia is confirmed by
the high crude mortality rate found in the European Confedera-
tion ofMedicalMycology (ECMM) survey (38%) (37–39), as well
as in Finland (35%) (40) and in the Barcelona area (44%) (8). In
our series, patients with candidemia had a crude 30-day mortality
rate of 39.9%. A major finding of the present study is the high
mortality rate for candidemia in patients admitted to hemato-
oncology and internal medicine wards compared with other
wards (44.4% versus 35.4%; P 0.002). Several factors may have
impacted the outcome, e.g., the high APACHE II score, patient
age, and the presence of multiple comorbidities. Therefore, it is
reasonable to assume that these factors played a major role in the
poor outcomes in internal medicine wards compared to other
wards. Thus, factors that may lead to intervention should be ex-
plored in future studies.
Certainly, the severity of a patient’s underlying medical condi-
tion greatly influences the crude mortality rate in these patient
populations; however, for patients in internal medicine wards,
inappropriate therapy (consisting mostly of omission of initial
empirical therapy and an inadequate choice of antifungals) might
represent an important variable that has been associated with in-
creased mortality rates (41).
Finally, the current study has several limitations that should be
kept in mind when interpreting the results. All five sites we ana-
lyzed were located in teaching institutions, and our observations
may not be generalizable to all patients with candidemia. Impor-
tant intrahospital differences may also be observed in the larger
hospitals. Another limitation of our study is that although 5 cen-
ters from 2 European countries participated, the results may not
be representative of each country.
This report shows that candidemia is a significant source of
morbidity in Italy and Spain, causing substantial burdens of dis-
ease, mortality, and likely high costs associated with care. Deter-
mining the factors associated with high rates of candidemia may
lead to the identification of measures that can help prevent dis-
ease.
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